Results for resectable translation from English to Maltese

masitinib treatment should only be used in dogs with non-resectable mast cell tumours and which express the mutated c-kit tyrosine kinase receptor.
it-trattament b’masitinib għandu jintuża biss fi klieb li jkollhom tumuri tal-mast cell li ma jkunux jistgħu jitneħħew u li jesprimu r-riċettur mibdul tal-c-kit tyrosine kinase.

treatment of non-resectable dog mast cell tumours (grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor
trattament ta ’ tumuri tal- mast cell (grad 2 jew 3) fil- kelb li ma jistgħux jitneħħew, b’ riċettur mibdul ikkonfermat tal- c- kit tyrosine kinase

treatment of non-resectable dog mast cell tumours (grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor.
trattament ta’ tumuri tal-mast cell (grad 2 jew 3) fil-klieb u li ma jistgħux jitneħħew, b’riċettur mibdul ikkonfermat tal-c-kit tyrosine kinase.

masivet is for the treatment of dogs with non-resectable mast cell tumours (grade 2 or 3) with a confirmed mutated c-kit tyrosine kinase receptor.
masivet jintuża għat-trattament ta’ klieb li jkollhom tumuri tal-mast cell (grad 2 jew 3) li ma jistgħux jitneħħew, b’riċettur mibdul ikkonfermat tal-c-kit tyrosine kinase.

limited data with other gadolinium contrast agents suggests that for the exclusion of additional cranial metastases in a patient with a known solitary resectable metastasis, an mr exam with the injection of 0.3 mmol/ kg body weight of optimark may lead to higher diagnostic confidence.
informazzjoni limitata dwar sustanzi oħrajn tal- kuntrast ta ’ gadolinium tissuġġerixxi li għall - esklużjoni ta ’ metastasi kranjali addizzjonali f’ pazjent b’ metastasi solitarja magħrufa li tista ’ tinqata ’, eżami ta ’ mr b’ injezzjoni tad- doża ta ’ 0. 3 mmol/ kg piż tal- ġisem ta ’ optimark, jista ’ jwassal għal kunfidenza dijanjostika ogħla.

the committee for medicinal products for veterinary use (cvmp) concluded that the benefits of masivet exceed the risks for the treatment of non-resectable mast cell tumours (grade 2 or 3) that have a confirmed mutated c-kit tyrosine kinase receptor and recommended that masivet be given a marketing authorisation.
il-kumitat għall-prodotti mediċinali għall-użu veterinarju (cvmp) ikkonkluda li l-benefiċċji ta’ masivet jisbqu r-riskji għall-kura ta’ tumuri taċ-ċelluli mast li ma jistgħux jitneħħew (bil- kirurġija) (grad 2 jew 3) li għandhom riċettur c-kit tyrosine kinase mibdul b’mod ġenetiku kkonfermat u rrakkomanda li masivet jingħata awtorizzazzjoni għat-tqegħid fis-suq.